Ascendis Health Limited
ASC.JO
Johannesburg Stock Exchange92.00
ZAc
- -
- -
ISIN
ZAE000185005
Return %
Stock
S&P500
1Y
2.22
26.53
3Y
67.27
76.60
5Y
17.95
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- A. Carl Neethling
- Full Time Employees
- 3,200
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 31 Georgian Crescent East Johannesburg South Africa 2191
- IPO Date
- Nov 22, 2013
- Website
- ascendishealth.com
- Similar Companies
- Business
- Ascendis Health Limited (ASC.JO), an investment holding company in the health and wellness sector, markets and distributes a portfolio of leading consumer health brands, specialty ingredients, compounded medicines, and clinical and diagnostic medical devices primarily in South Africa. The company operates through two main segments: Consumer Health, encompassing Ascendis Consumer Brands (health and wellness products such as natural supplements, multi-vitamins, minerals, nutraceuticals, homeopathics, herbals, and body/skin care under brands including Bettaway, Chela-Fer, Chela Preg, Chela Mag, Junglevites, Menacal 7, Solal, Vitaforce, Nimue, and Scitec), Chempure (specialty ingredients), and The Compounding Pharmacy of South Africa (compounded medicines and supplements); and Medical Devices, distributed via The Scientific Group (clinical diagnostics, life sciences, point-of-care), Surgical Innovations (surgical and acute care), Ortho-Xact (orthopaedic trauma, limb reconstruction, sports medicine), Cardio Tech (cardiovascular and respiratory), and InterV-Med (endoscopic solutions, acute care therapies), featuring diagnostic laboratory equipment, consumables, surgical tools, and radiology devices under brands such as Reuterina, Pharmachem, Sinucon, Phlexy, Clonam, RCA, and The Scientific Group. Ascendis Health Limited, founded in 2008 and headquartered in Sandton, Johannesburg, South Africa, listed on the Johannesburg Stock Exchange's General Segment in 2013 and maintains a presence across Africa with select exports to Europe, the Middle East, and Australia, serving pharmacies, private hospitals, doctors, and government entities. In a major strategic shift effective July 1, 2024, the group transitioned to an Investment Entity under IFRS 10, deconsolidating subsidiaries and measuring investments at fair value through profit or loss per IFRS 9 to enhance transparency, capital allocation, and shareholder value via investment income and capital appreciation managed by ACN Capital IHC; this resulted in a net asset value of R659m as of December 31, 2024, with Consumer Health at 65% and Medical Devices at 35%. Recent operational changes include the successful completion of Surgical Innovations' business rescue process in 2023 with strengthened supplier relationships; consolidation of Cardio Tech (CardaXes) and InterV-Med operations during 2024 for optimized customer bases and product synergies, followed by their merger effective January 1, 2025; Ortho-Xact's acquisition of two strategic orthopaedic agencies; onboarding of new agencies by The Scientific Group; a strategic acquisition by Ascendis Consumer Brands in the weight management segment; and portfolio rationalization through discontinued sub-optimal agency relationships to boost profitability.